| Literature DB >> 33518345 |
Tianmin Li1, Claudia D Castañeda1, Julio Miotto1, Chris McDaniel1, Aaron S Kiess1, Li Zhang2.
Abstract
Avian pathogenic Escherichia coli (APEC) causes colibacillosis in poultry, which has been traditionally controlled by the prophylactic in-feed supplementation of antibiotics. However, antibiotics are being removed from poultry diets owing to the emergence of multidrug-resistant (MDR) bacteria. Therefore, alternatives to control APEC are required. This study aimed to evaluate the effects of in ovo inoculation of probiotics on the incidence of APEC in broilers and evaluate the virulence and antimicrobial resistance properties of the APEC isolates. On embryonic day 18, 4 in ovo treatments (T) were applied: T1 (Marek's vaccine [MV]), T2 (MV and Lactobacillus animalis), T3 (MV and Lactobacillus reuteri), and T4 (MV and Lactobacillus rhamnosus). A total of 180 male broilers per treatment were randomly placed in 10 pens. The heart, liver, spleen, and yolk sac were collected on day 0, 14, 28, and 42. Presumptive E. coli isolates were confirmed by real-time PCR. The positive isolates were screened for the APEC-related genes (iroN, ompT, hlyF, iss, and iutA), and E. coli isolates containing one or more of these genes were identified as APEC-like strains. A total of 144 APEC-like isolates were isolated from 548 organ samples. No differences (P > 0.05) among treatments were observed for the incidence of APEC-like strains in all organs when averaged over sampling days. However, when averaged over treatments, the incidence in the heart, liver, and yolk sac was different among sampling days; a significant increase was observed in these organs on day 14 compared with day 0. Twenty-five antimicrobial resistance genes were evaluated for all APEC-like isolates, and 92.4% of the isolates carried at least one antimicrobial resistance gene. Thirty-seven isolates were then selected for antimicrobial susceptibility testing; MDR strains accounted for 37.8% of the isolates. In conclusion, the in ovo inoculation of a single probiotic strain did not confer protection against APEC strains in broilers. The high prevalence of MDR isolates indicates that further research on antibiotic alternatives is required to prevent APEC infections in broilers.Entities:
Keywords: Lactobacillus; in ovo inoculation; multidrug-resistant; real-time PCR detection; virulence gene
Mesh:
Substances:
Year: 2020 PMID: 33518345 PMCID: PMC7936151 DOI: 10.1016/j.psj.2020.11.072
Source DB: PubMed Journal: Poult Sci ISSN: 0032-5791 Impact factor: 3.352
Primers used for amplification.
| Primer | Sequence (5′–3′) | Size (bp) | Reference | |
|---|---|---|---|---|
| Forward | Reverse | |||
| Minimal predictors of APEC virulence genes | ||||
| | AATCCGGCAAAGAGACGAACCGCCT | GTTCGGGCAACCCCTGCTTTGACTTT | 553 | |
| | TCATCCCGGAAGCCTCCCTCACTACTAT | TAGCGTTTGCTGCACTGGCTTCTGATAC | 496 | |
| | GGCCACAGTCGTTTAGGGTGCTTACC | GGCGGTTTAGGCATTCCGATACTCAG | 450 | |
| | CAGCAACCCGAACCACTTGATG | AGCATTGCCAGAGCGGCAGAA | 323 | |
| | GGCTGGACATCATGGGAACTGG | CGTCGGGAACGGGTAGAATCG | 302 | |
| Antimicrobial resistance genes | ||||
| | ATGTGCGCGGAACCCCTATTTGTTTA | AAAAAGCGGTTAGCTCCTTCGGTCCT | 558 | |
| | GGCACCCGCGACGCCCTGGTCCAAAAG | GGGCCCGGCGCCGATCGACAGGATTT | 502 | |
| | GGGCAAGCGCCGCGTCACTTATT | CGCGGCGTTGTTTCGGCTTCA | 302 | |
| | TCGGGCAATCAGGTGCGACAATCTA | TGCCAGCGCATCAACAATATTTTCACC | 378 | |
| | TAACGGCGCAGTGGCGGTTTTCA | AAGCTCGCCGCGTTGTTTCATCAAG | 365 | |
| | CGGGGCGACTGGGGCGGTAGC | CAAAGCGCGGCCGGCACCTGT | 372 | |
| | AACGCGTGAAGTGGTTCGGTTGGT | TTCGCCCCATTTAGTGGCTATTCTTC | 446 | |
| | ATCGGGAATGGCCCTGATA | CTTCCGGCTCGATGTCTATTGTAG | 328 | |
| | ATATCCCGTGGTCAGTAAAAGGTG | GACCCCCGCCAGAGACATA | 342 | |
| | CCCTTCCGCCGTTGTCATAATCG | TACAAAGCCCCACGCATCAAGC | 175 | This study |
| | TCGCCGCTGCCGCTTTTATCAGT | GCCAACAGTCGCGGGAGAAGGTG | 440 | |
| | CGCCGCTCTTAGACGCCCTGTCC | CGCCGCTCTTAGACGCCCTGTCC | 462 | |
| | CACTCCGGCACCGCCAACTTTC | GAACGGGCATGCGGATCAGTGAG | 545 | |
| Heavy metal resistance genes | ||||
| | CCACTGCGCGGAATTTCCACTCACCAT | ACGCCGTCCCGTCTGATGTTGACAAG | 231 | |
| | ATGCGCCGCCTGCCTGTTTACCTTGTTA | CGCGCTTGTGCTGCCGGAAGACA | 576 | |
| | CCGACAAACTTCCAGAAGATGGGGTAGT | GAGGCAGCGGTTGCATTTGTACTTGACG | 428 | |
| | CCTGGGGCCGTCAGCGGACCTG | TCCTTGCTGGTGGCCGTTCATACTTCAT | 302 | |
| | ATCCGGAAGGTCAGCACCGTCCATAGAC | GACCTCGCGGATGTCAGTGGCTACACCT | 507 | |
| | GGCGCCCAGAATGATAATCGCAACA | GGGCGTGGCGCTGGCTACACTT | 502 | |
| | GTGGGGCAGCTTTTGCTCAGTCCAGTGA | CGAAGCTTTCTTGCCTGCGTCTGATGTG | 385 | |
| | ACCCGCTTCATCAACCACTT | TGCCGATATGGGGATTTCCG | 268 | This study |
| | ACACCCCGGCCTGGGCTCCTT | TGCGGGCACGGGAACAAACCTC | 603 | |
| | GATCCGCGCCGCCCATATCGCCCATCTG | CACGCGCTCGCCGCCGTCGTTGAGTTG | 250 | |
Abbreviation: APEC, avian pathogenic Escherichia coli.
Virulence profile of APEC isolates.
| Virulence profile | Number of virulence factors present | Frequency (n = 548) | Percentage |
|---|---|---|---|
| 5 | 15 | 2.7% | |
| 4 | 72 | 13.1% | |
| 4 | 2 | 0.4% | |
| 3 | 53 | 9.7% | |
| 2 | 2 | 0.4% | |
| Total | 144 | 26.3% |
Abbreviation: APEC, avian pathogenic Escherichia coli.
Prevalence of APEC isolated from different organs in each treatment.
| Treatment | Sampling organ (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Heart | SEM | Liver | SEM | Spleen | SEM | Yolk sac | SEM | |
| Marek's vaccine (MV) | 27.5 | 7.10 | 22.5 | 6.31 | 27.5 | 15.10 | 33.3 | 11.97 |
| MV and | 27.5 | 7.10 | 32.5 | 8.05 | 22.5 | 11.21 | 38.5 | 15.80 |
| MV and | 32.5 | 7.88 | 30.0 | 7.67 | 22.5 | 11.21 | 11.1 | 6.81 |
| MV and | 22.5 | 6.21 | 20.0 | 5.80 | 22.5 | 11.21 | 21.1 | 9.20 |
| 0.757 | 0.448 | 0.926 | 0.164 | |||||
| Day | ||||||||
| 0 | 5.0c | 3.39 | 5.0c | 3.31 | 0 | 0 | 15.0b | 5.37 |
| 14 | 52.5a | 7.94 | 57.5a | 7.91 | 35.0 | 7.76 | 39.3a | 10.50 |
| 28 | 35.0a,b | 7.57 | 20.0b,c | 6.28 | 35.0 | 7.76 | ||
| 42 | 17.5b,c | 5.98 | 22.5b | 6.58 | 25.0 | 6.85 | ||
| | 0.0003 | <0.0001 | 0.747 | 0.015 | ||||
a–cMeans in a column not sharing a common superscript were different (P < 0.05).
Abbreviation: APEC, avian pathogenic Escherichia coli.
Results of antimicrobial resistance gene detection.
| Resistance genes | Resistance profile | Number of resistant isolates (%) | Number of resistance isolates in each treatment (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Marek's vaccine (MV) | SEM | MV and | SEM | MV and | SEM | MV and | SEM | ||||
| β-Lactamase | 16 (11.1) | 7 (18.9) | 0.065 | 1 (2.4) | 0.024 | 5 (13.9) | 0.058 | 3 (10) | 0.054 | 0.212 | |
| Aminoglycoside | 24 (16.7) | 5 (13.5) | 0.057 | 9 (22.0) | 0.065 | 9 (25.0) | 0.073 | 1 (3.3) | 0.033 | 0.149 | |
| 21 (14.6) | 3 (8.1) | 0.045 | 11 (26.8) | 0.070 | 6 (16.7) | 0.063 | 1 (3.3) | 0.033 | 0.052 | ||
| 19 (13.2) | 3 (8.1) | 0.045 | 2 (4.9) | 0.034 | 7 (19.4) | 0.067 | 7 (23.3) | 0.079 | 0.095 | ||
| 21 (14.6) | 4 (10.8) | 0.052 | 8 (19.5) | 0.063 | 8 (22.2) | 0.070 | 1 (3.3) | 0.033 | 0.178 | ||
| Tetracycline | 55 (38.2) | 13 (35.1) | 0.080 | 20 (48.8) | 0.079 | 15 (41.7) | 0.083 | 7 (23.3) | 0.079 | 0.178 | |
| 11 (7.6) | 1 (2.7) | 0.027 | 4 (9.8) | 0.047 | 2 (5.6) | 0.014 | 4 (2.8) | 0.063 | 0.428 | ||
| Trimethoprim | 8 (5.6) | 0 | 0 | 7 (17.1) | 0.059 | 1 (2.8) | 0.028 | 0 | 0 | 0.354 | |
| 51 (35.4) | 19 (51.4) | 0.083 | 12 (29.3) | 0.072 | 14 (38.9) | 0.082 | 6 (20.0) | 0.074 | 0.052 | ||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Quaternary ammonium compounds | 68 (47.2) | 12 (32.4)b | 0.078 | 27 (65.9)a | 0.075 | 21 (58.3)a | 0.083 | 8 (26.7)b | 0.082 | 0.002 | |
| Quinolone | 47 (32.6) | 19 (51.4) | 0.083 | 16 (39.0) | 0.079 | 12 (33.3) | 0.080 | 0 | 0 | 0.467 | |
| Sulfa | 21 (14.6) | 3 (8.1) | 0.045 | 9 (22.0) | 0.065 | 8 (22.2) | 0.070 | 1 (3.3) | 0.033 | 0.093 | |
| Integrase | 29 (20.1) | 2 (5.4)b | 0.038 | 17 (41.5)a | 0.078 | 9 (25.0)a | 0.073 | 1 (3.3)b | 0.033 | 0.001 | |
| Arsenic | 137 (95.1) | 36 (97.3%) | 0.027 | 38 (92.7) | 0.041 | 35 (97.2) | 0.028 | 28 (93.3) | 0.046 | 0.716 | |
| Mercury | 29 (20.1) | 7 (18.9) | 0.065 | 8 (19.5) | 0.063 | 9 (25.0) | 0.073 | 5 (16.7) | 0.069 | 0.851 | |
| Tellurite | 5 (3.5) | 2 (5.4) | 0.038 | 2 (4.9) | 0.034 | 0 | 0 | 1 (3.3) | 0.033 | 0.982 | |
| 4 (2.8) | 2 (5.4) | 0.038 | 2 (4.9) | 0.034 | 0 | 0 | 0 | 0 | 0.999 | ||
| 3 (2.1) | 2 (5.4) | 0.038 | 1 (2.4) | 0.024 | 0 | 0 | 0 | 0 | 0.930 | ||
| 4 (2.8) | 2 (5.4) | 0.038 | 2 (4.9) | 0.034 | 0 | 0 | 0 | 0 | 0.999 | ||
| Copper | 2 (5.4) | 2 (1.4) | 0.038 | 0 | 0 | 0 | 0 | 0 | 0 | 0.999 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||
| 3 (2.1) | 0 | 0 | 0 | 0 | 0 | 0 | 3 (10.0) | 0.056 | 0.999 | ||
| Silver | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 1 (0.7) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (3.3) | 0.033 | 0.999 | ||
a–cMeans in a column not sharing a common superscript were different (P < 0.05).
Results of antimicrobial susceptibility testing.
| Antibiotic agents tested | Antimicrobial class | Number of resistant strains, n = 37 |
|---|---|---|
| Amoxicillin/clavulanic acid (AUG2) | β-Lactam combination agents | 8 (21.6%) |
| Ampicillin (AMP) | Penicillins | 16 (43.2%) |
| Azithromycin (AZI) | Macrolides | 0 |
| Cefoxitin (FOX) | Cephems | 8 (21.6%) |
| Ceftriaxone (AXO) | Cephems | 8 (21.6%) |
| Chloramphenicol (CHL) | Phenicols | 0 |
| Ciprofloxacin (CIP) | Quinolones | 0 |
| Gentamicin (GEN) | Aminoglycosides | 17 (45.9%) |
| Meropenem (MERO) | Penems | 0 |
| Nalidixic Acid (NAL) | Quinolones | 0 |
| Streptomycin (STR) | Aminoglycosides | 11 (29.7%) |
| Sulfisoxazole (FIS) | Folate pathway antagonists | 11 (29.7%) |
| Tetracycline (TET) | Tetracyclines | 23 (62.2%) |
| Trimethoprim/sulfamethoxazole (SXT) | Folate pathway antagonists | 6 (16.2%) |
Antimicrobial resistance patterns of the tested APEC isolates against 14 antimicrobial agents.
| Resistance pattern | Antimicrobial class | No. of antimicrobial class | No. of resistant isolates | Percentage |
|---|---|---|---|---|
| AUG2, AMP, FOX, AXO, GEN, STR, FIS, TET | β-Lactam combination agents, penicillins, cephems, aminoglycosides, folate pathway antagonists, tetracyclines | 6 | 8 | 21.6% |
| AMP, STR, TET, FIS, SXT | Penicillins, aminoglycosides, tetracyclines, folate pathway antagonists | 4 | 2 | 5.4% |
| GEN, TET, SXT | Aminoglycosides, tetracyclines, folate pathway antagonists | 3 | 4 | 10.8% |
| AMP, TET | Penicillins, tetracyclines | 2 | 4 | 10.8% |
| AMP, GEN | Penicillins, aminoglycosides | 2 | 2 | 5.4% |
| GEN, TET | Aminoglycosides, tetracyclines | 2 | 2 | 5.4% |
| GEN, STR, FIS | Aminoglycosides, folate pathway antagonists | 2 | 1 | 2.7% |
| TET | Tetracyclines | 1 | 3 | 8.1% |
| None | None | 0 | 11 | 29.7% |
Abbreviations: AMP, ampicillin; APEC, avian pathogenic Escherichia coli; AUG2, amoxicillin/clavulanic acid; AXO, ceftriaxone; FIS, sulfisoxazole; FOX, cefoxitin; GEN, gentamicin; STR, streptomycin; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline.